Navigation Links
Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
Date:11/13/2007

Time Resolved Light Induced Fluorescence Spectroscopy (TR-LIFS) to be Combined with Other PMI Diagnostic Technologies to Help Prevent Deaths

Related to Heart Attacks

DOYLESTOWN, Pa., Nov. 13 /PRNewswire/ -- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, announces the acquisition of a new technology that identifies and quantifies metabolic activity and inflammation in human artery tissue by measuring the time it takes for light to dissipate after the tissue has been excited with ultra-short light pulses.

The new technique, called Time Resolved Light Induced Fluorescence Spectroscopy (TR-LIFS), exploits the phenomenon that bi-products of metabolic activity behave differently than surrounding tissue. In TR-LIFS, a short light pulse (picoseconds) is used to excite the tissue, and then the resulting light that emanates from the tissue is monitored over a brief time span (several nanoseconds). This technology has been verified by several research groups to accurately detect inflammation in human tissue in vitro and in vivo.

Arterial plaques are associated with an array of biochemical, functional, and structural changes that can be readily identified with optical techniques. Another Prescient Medical technology, Raman spectroscopy, has been proven to provide exquisite compositional detail, in vivo, of arterial wall constituents and will be entering clinical trials early next year. By combining TR-LIFS with Raman spectroscopy, Prescient's burgeoning arsenal of tools to assist physicians in assessing plaque vulnerability is buttressed with a formidable new diagnostic weapon.

"We believe the development of TR-LIFS technology into a diagnostic product will provide another valuable tool in the fight against heart disease," said Patricia Scheller, Prescient's chief executive officer. "Since 80 percent of all heart attacks are caused by soft plaques that suddenly rupture, identifying these plaques will allow physicians to treat these plaques pro-actively, before a major heart attack can occur. Prescient is actively working with interventional cardiologists to pursue and develop technologies that will greatly advance their ability to diagnose and treat the full spectrum of coronary plaques."

"TR-LIFS is particularly well suited to detecting macrophages, cells that are strongly correlated with inflammation. Inflamed coronary plaques are at risk of causing a heart attack or other coronary event. Prescient Medical plans to integrate TR-LIFS technology into its vPredict(TM) Optical Catheter System, a revolutionary intravascular diagnostic instrument that is currently in development. "TR-LIFS will greatly expand the capabilities of the vPredict Optical Catheter System. Not only will we have information on the composition of coronary plaques, but we will now also be able to identify its metabolic state, which will help interventional cardiologists tailor treatment to each patient's unique needs," according to Ms. Scheller.

In addition to the development of TR-LIFS, PMI is expected to commence the clinical trials of several other revolutionary diagnostic and treatment approaches in 2008. This will include the first human clinical studies of the stent-like vProtect(TM) Luminal Shield, a prosthesis that treats soft coronary plaques, and the vPredict(TM) Optical Catheter System, a diagnostic catheter designed to analyze and quantify the chemical composition of arterial plaque and assess its vulnerability to rupture.

Each year, one in every 100 Americans over the age of 35 will suffer a coronary event. Of these victims, over one million of them will suffer a heart attack caused by the sudden rupture of soft plaque hidden inside the artery wall. This type of plaque is believed to be the major culprit in up to 80 percent of all heart attacks.

About Prescient Medical, Inc. (PMI)

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at http://www.prescientmedical.com or call 866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
2. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
3. U.S. Preventive Medicine Acquires Specialty Disease Management
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
6. Novel Technology Breaks Through Cancer Pain
7. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
10. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
11. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):